2,497 reports of this reaction
2.3% of all MOMETASONE FUROATE reports
#9 most reported adverse reaction
FATIGUE is the #9 most commonly reported adverse reaction for MOMETASONE FUROATE, manufactured by L. Perrigo Company. There are 2,497 FDA adverse event reports linking MOMETASONE FUROATE to FATIGUE. This represents approximately 2.3% of all 107,848 adverse event reports for this drug.
MOMETASONE FUROATE has an overall safety score of 78 out of 100. Patients taking MOMETASONE FUROATE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for MOMETASONE FUROATE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for MOMETASONE FUROATE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,497 FDA reports for MOMETASONE FUROATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.3% of all adverse event reports for MOMETASONE FUROATE, making it a notable side effect.
If you experience fatigue while taking MOMETASONE FUROATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.